Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Total Valuation
Milestone Pharmaceuticals has a market cap or net worth of $122.37M. The enterprise value is $74.66M.
Market Cap$122.37M
Enterprise Value$74.66M
Share Statistics
Milestone Pharmaceuticals has 117,667,274 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding117,667,274
Owned by Insiders1.36%
Owned by Institutions16.54%
Financial Efficiency
Milestone Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -62.00%.
Return on Equity (ROE)-1.51
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-62.00%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee46.85K
Profits Per Employee-1.91M
Employee Count33
Asset Turnover0.01
Inventory Turnover0.18
Valuation Ratios
The current PE Ratio of Milestone Pharmaceuticals is ―. Milestone Pharmaceuticals’s PEG ratio is -0.23.
PE Ratio―
PS Ratio109.60
PB Ratio4.06
Price to Fair Value4.06
Price to FCF-3.43
Price to Operating Cash Flow-1.78
PEG Ratio-0.23
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of 1.55M and earned -63.06M in profits. Earnings per share was -0.75.
Revenue1.55M
Gross Profit1.43M
Operating Income-62.48M
Pretax Income-63.40M
Net Income-63.06M
EBITDA-62.14M
Earnings Per Share (EPS)-0.75
Cash Flow
In the last 12 months, operating cash flow was -49.11M and capital expenditures -29.98K, giving a free cash flow of -49.14M billion.
Operating Cash Flow-49.11M
Free Cash Flow-49.14M
Free Cash Flow per Share-0.42
Dividends & Yields
Milestone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change18.18%
50-Day Moving Average1.72
200-Day Moving Average1.89
Relative Strength Index (RSI)24.88
Average Volume (3m)1.66M
Important Dates
Milestone Pharmaceuticals upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateMar 20, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Milestone Pharmaceuticals as a current ratio of 8.01, with Debt / Equity ratio of 139.76%
Current Ratio8.01
Quick Ratio7.96
Debt to Market Cap0.34
Net Debt to EBITDA0.24
Interest Coverage Ratio-16.28
Taxes
In the past 12 months, Milestone Pharmaceuticals has paid -345.00K in taxes.
Income Tax-345.00K
Effective Tax Rate<0.01
Enterprise Valuation
Milestone Pharmaceuticals EV to EBITDA ratio is -2.49, with an EV/FCF ratio of -3.14.
EV to Sales100.11
EV to EBITDA-2.49
EV to Free Cash Flow-3.14
EV to Operating Cash Flow-3.16
Balance Sheet
Milestone Pharmaceuticals has $105.96M in cash and marketable securities with $58.38M in debt, giving a net cash position of $47.58M billion.
Cash & Marketable Securities$105.96M
Total Debt$58.38M
Net Cash$47.58M
Net Cash Per Share$0.40
Tangible Book Value Per Share$0.50
Margins
Gross margin is 96.18%, with operating margin of -4041.72%, and net profit margin of -4078.78%.
Gross Margin96.18%
Operating Margin-4041.72%
Pretax Margin-4101.10%
Net Profit Margin-4078.78%
EBITDA Margin-4019.40%
EBIT Margin-4041.72%
Analyst Forecast
The average price target for Milestone Pharmaceuticals is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside669.23% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast3.70%